Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 24,441 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,441 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $3.34, for a total value of $81,632.94. Following the sale, the chief executive officer owned 5,962,502 shares of the company’s stock, valued at $19,914,756.68. This trade represents a 0.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Sight Sciences Price Performance

Shares of NASDAQ:SGHT opened at $3.29 on Friday. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $6.29. The stock has a fifty day moving average of $3.74 and a 200-day moving average of $3.47. The company has a market capitalization of $172.30 million, a PE ratio of -3.43 and a beta of 2.41. The company has a debt-to-equity ratio of 0.57, a quick ratio of 9.49 and a current ratio of 10.01.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Sight Sciences had a negative return on equity of 59.38% and a negative net margin of 64.23%.The company had revenue of $19.56 million during the quarter, compared to the consensus estimate of $18.18 million. Sight Sciences has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC raised its holdings in shares of Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after acquiring an additional 3,137 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Sight Sciences during the fourth quarter worth $36,000. Tower Research Capital LLC TRC raised its holdings in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after acquiring an additional 2,875 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Sight Sciences during the second quarter worth $49,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of Sight Sciences by 38.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock worth $66,000 after acquiring an additional 4,453 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on SGHT. Piper Sandler restated a “neutral” rating and issued a $4.00 target price (up previously from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Wall Street Zen upgraded Sight Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Thursday, August 28th. Citigroup increased their target price on Sight Sciences from $3.60 to $4.50 and gave the company a “neutral” rating in a report on Thursday, August 21st. Finally, Morgan Stanley increased their target price on Sight Sciences from $3.00 to $4.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.42.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.